Magnetic  ||| S:0 E:9 ||| JJ
gold  ||| S:9 E:14 ||| NN
nanoparticle-mediated  ||| S:14 E:36 ||| JJ
small  ||| S:36 E:42 ||| JJ
interference  ||| S:42 E:55 ||| NN
RNA  ||| S:55 E:59 ||| NNP
silencing  ||| S:59 E:69 ||| VBD
Bag-1  ||| S:69 E:75 ||| CD
gene  ||| S:75 E:80 ||| NN
for  ||| S:80 E:84 ||| IN
colon  ||| S:84 E:90 ||| NN
cancer  ||| S:90 E:97 ||| NN
therapy  ||| S:97 E:105 ||| NN
Bcl-2-associated  ||| S:105 E:122 ||| CD
athanogene 1  ||| S:122 E:135 ||| CD
( ||| S:135 E:136 ||| -LRB-
Bag-1 ||| S:136 E:141 ||| NNP
)  ||| S:141 E:143 ||| -RRB-
is  ||| S:143 E:146 ||| VBZ
a  ||| S:146 E:148 ||| DT
positive  ||| S:148 E:157 ||| JJ
regulator  ||| S:157 E:167 ||| NN
of  ||| S:167 E:170 ||| IN
Bcl-2  ||| S:170 E:176 ||| NNP
which  ||| S:176 E:182 ||| WDT
is  ||| S:182 E:185 ||| VBZ
an  ||| S:185 E:188 ||| DT
anti-apoptotic  ||| S:188 E:203 ||| JJ
gene ||| S:203 E:207 ||| NN
.  ||| S:207 E:209 ||| .
Bag-1  ||| S:209 E:215 ||| NNP
was  ||| S:215 E:219 ||| VBD
very  ||| S:219 E:224 ||| RB
slightly  ||| S:224 E:233 ||| RB
expressed  ||| S:233 E:243 ||| VBN
in  ||| S:243 E:246 ||| IN
normal  ||| S:246 E:253 ||| JJ
tissues ||| S:253 E:260 ||| NNS
,  ||| S:260 E:262 ||| ,
but  ||| S:262 E:266 ||| CC
often  ||| S:266 E:272 ||| RB
highly  ||| S:272 E:279 ||| RB
expressed  ||| S:279 E:289 ||| VBN
in  ||| S:289 E:292 ||| IN
many  ||| S:292 E:297 ||| JJ
tumor  ||| S:297 E:303 ||| NN
tissues ||| S:303 E:310 ||| NNS
,  ||| S:310 E:312 ||| ,
particularly  ||| S:312 E:325 ||| RB
in  ||| S:325 E:328 ||| IN
colon  ||| S:328 E:334 ||| NN
cancer ||| S:334 E:340 ||| NN
,  ||| S:340 E:342 ||| ,
which  ||| S:342 E:348 ||| WDT
can  ||| S:348 E:352 ||| MD
promote  ||| S:352 E:360 ||| VB
metastasis ||| S:360 E:370 ||| NNS
,  ||| S:370 E:372 ||| ,
poor  ||| S:372 E:377 ||| JJ
prognosis  ||| S:377 E:387 ||| NN
and  ||| S:387 E:391 ||| CC
anti-apoptotic  ||| S:391 E:406 ||| JJ
function  ||| S:406 E:415 ||| NN
of  ||| S:415 E:418 ||| IN
colon  ||| S:418 E:424 ||| NN
cancer ||| S:424 E:430 ||| NN
.  ||| S:430 E:432 ||| .
We  ||| S:432 E:435 ||| PRP
prepared  ||| S:435 E:444 ||| VBD
and  ||| S:444 E:448 ||| CC
evaluated  ||| S:448 E:458 ||| JJ
magnetic  ||| S:458 E:467 ||| JJ
gold  ||| S:467 E:472 ||| NN
nanoparticle ||| S:472 E:484 ||| FW
/ ||| S:484 E:485 ||| FW
Bag-1  ||| S:485 E:491 ||| FW
siRNA  ||| S:491 E:497 ||| FW
recombinant  ||| S:497 E:509 ||| FW
plasmid  ||| S:509 E:517 ||| FW
complex ||| S:517 E:524 ||| FW
,  ||| S:524 E:526 ||| ,
a  ||| S:526 E:528 ||| DT
gene  ||| S:528 E:533 ||| NN
therapy  ||| S:533 E:541 ||| NN
system ||| S:541 E:547 ||| NN
,  ||| S:547 E:549 ||| ,
which  ||| S:549 E:555 ||| WDT
can  ||| S:555 E:559 ||| MD
transfect  ||| S:559 E:569 ||| VB
cells  ||| S:569 E:575 ||| NNS
efficiently ||| S:575 E:586 ||| RB
,  ||| S:586 E:588 ||| ,
for  ||| S:588 E:592 ||| IN
both  ||| S:592 E:597 ||| DT
therapeutic  ||| S:597 E:609 ||| JJ
effect  ||| S:609 E:616 ||| NN
and  ||| S:616 E:620 ||| CC
safety  ||| S:620 E:627 ||| NN
in vitro  ||| S:627 E:636 ||| VBZ
mainly  ||| S:636 E:643 ||| RB
by  ||| S:643 E:646 ||| IN
electrophoretic  ||| S:646 E:662 ||| JJ
mobility  ||| S:662 E:671 ||| JJ
shift  ||| S:671 E:677 ||| NN
assays ||| S:677 E:683 ||| NN
,  ||| S:683 E:685 ||| ,
flow  ||| S:685 E:690 ||| NN
cytometric  ||| S:690 E:701 ||| NN
analyses ||| S:701 E:709 ||| NNS
,  ||| S:709 E:711 ||| ,
cell  ||| S:711 E:716 ||| NN
viability  ||| S:716 E:726 ||| NN
assays ||| S:726 E:732 ||| NN
,  ||| S:732 E:734 ||| ,
western  ||| S:734 E:742 ||| JJ
blot  ||| S:742 E:747 ||| JJ
analyses  ||| S:747 E:756 ||| NNS
and  ||| S:756 E:760 ||| CC
RT-PCR  ||| S:760 E:767 ||| NNP
( ||| S:767 E:768 ||| -LRB-
real-time ||| S:768 E:777 ||| JJ
)  ||| S:777 E:779 ||| -RRB-
assays ||| S:779 E:785 ||| NN
.  ||| S:785 E:787 ||| .
Magnetic  ||| S:787 E:796 ||| JJ
gold  ||| S:796 E:801 ||| NN
nanoparticle ||| S:801 E:813 ||| FW
/ ||| S:813 E:814 ||| FW
Bag-1  ||| S:814 E:820 ||| FW
siRNA  ||| S:820 E:826 ||| FW
recombinant  ||| S:826 E:838 ||| FW
plasmid  ||| S:838 E:846 ||| FW
complex  ||| S:846 E:854 ||| NN
was  ||| S:854 E:858 ||| VBD
successfully  ||| S:858 E:871 ||| RB
transfected  ||| S:871 E:883 ||| VBN
into  ||| S:883 E:888 ||| IN
LoVo  ||| S:888 E:893 ||| JJ
colon  ||| S:893 E:899 ||| NN
cancer  ||| S:899 E:906 ||| NN
cells  ||| S:906 E:912 ||| NNS
and  ||| S:912 E:916 ||| CC
the  ||| S:916 E:920 ||| DT
exogenous  ||| S:920 E:930 ||| JJ
gene  ||| S:930 E:935 ||| NN
was  ||| S:935 E:939 ||| VBD
expressed  ||| S:939 E:949 ||| VBN
in  ||| S:949 E:952 ||| IN
the  ||| S:952 E:956 ||| DT
cells ||| S:956 E:961 ||| NNS
.  ||| S:961 E:963 ||| .
Flow  ||| S:963 E:968 ||| NN
cytometric  ||| S:968 E:979 ||| NN
results  ||| S:979 E:987 ||| NNS
showed  ||| S:987 E:994 ||| VBD
apoptosis  ||| S:994 E:1004 ||| JJ
rate  ||| S:1004 E:1009 ||| NN
was  ||| S:1009 E:1013 ||| VBD
significantly  ||| S:1013 E:1027 ||| RB
increased ||| S:1027 E:1036 ||| VBN
.  ||| S:1036 E:1038 ||| .
In  ||| S:1038 E:1041 ||| IN
MTT  ||| S:1041 E:1045 ||| NNP
assays ||| S:1045 E:1051 ||| NN
,  ||| S:1051 E:1053 ||| ,
magnetic  ||| S:1053 E:1062 ||| JJ
gold  ||| S:1062 E:1067 ||| NN
nanoparticles  ||| S:1067 E:1081 ||| NNS
revealed  ||| S:1081 E:1090 ||| VBD
lower  ||| S:1090 E:1096 ||| JJR
cytotoxicity  ||| S:1096 E:1109 ||| NN
than  ||| S:1109 E:1114 ||| IN
Lipofectamine 2000  ||| S:1114 E:1133 ||| FW
transfection  ||| S:1133 E:1146 ||| FW
reagents  ||| S:1146 E:1155 ||| FW
( ||| S:1155 E:1156 ||| -LRB-
P  ||| S:1156 E:1157 ||| NNP
< ||| S:1157 E:1158 ||| SYM
0.05 ||| S:1158 E:1162 ||| CD
) ||| S:1162 E:1163 ||| -RRB-
.  ||| S:1163 E:1165 ||| .
Both  ||| S:1165 E:1170 ||| DT
in  ||| S:1170 E:1173 ||| IN
western  ||| S:1173 E:1181 ||| JJ
blot  ||| S:1181 E:1186 ||| JJ
analyses  ||| S:1186 E:1195 ||| NNS
and  ||| S:1195 E:1199 ||| CC
RT-PCR  ||| S:1199 E:1206 ||| JJ
assays ||| S:1206 E:1212 ||| NN
,  ||| S:1212 E:1214 ||| ,
magnetic  ||| S:1214 E:1223 ||| JJ
gold  ||| S:1223 E:1228 ||| NN
nanoparticle ||| S:1228 E:1240 ||| FW
/ ||| S:1240 E:1241 ||| FW
Bag-1  ||| S:1241 E:1247 ||| FW
siRNA  ||| S:1247 E:1253 ||| FW
recombinant  ||| S:1253 E:1265 ||| FW
plasmid  ||| S:1265 E:1273 ||| FW
complex  ||| S:1273 E:1281 ||| FW
transfected  ||| S:1281 E:1293 ||| FW
cells  ||| S:1293 E:1299 ||| FW
demonstrated  ||| S:1299 E:1312 ||| FW
expression  ||| S:1312 E:1323 ||| NN
of  ||| S:1323 E:1326 ||| IN
Bag-1  ||| S:1326 E:1332 ||| NNP
mRNA  ||| S:1332 E:1337 ||| NNP
( ||| S:1337 E:1338 ||| -LRB-
P  ||| S:1338 E:1339 ||| NNP
< ||| S:1339 E:1340 ||| SYM
0.05 ||| S:1340 E:1344 ||| CD
)  ||| S:1344 E:1346 ||| -RRB-
and  ||| S:1346 E:1350 ||| CC
protein  ||| S:1350 E:1358 ||| NN
( ||| S:1358 E:1359 ||| -LRB-
P  ||| S:1359 E:1360 ||| NNP
< ||| S:1360 E:1361 ||| SYM
0.05 ||| S:1361 E:1365 ||| CD
)  ||| S:1365 E:1367 ||| -RRB-
was  ||| S:1367 E:1371 ||| VBD
decreased ||| S:1371 E:1380 ||| VBN
.  ||| S:1380 E:1382 ||| .
In  ||| S:1382 E:1385 ||| IN
further  ||| S:1385 E:1393 ||| JJ
study ||| S:1393 E:1398 ||| NN
,  ||| S:1398 E:1400 ||| ,
c-myc  ||| S:1400 E:1406 ||| JJ
and  ||| S:1406 E:1410 ||| CC
β-catenin  ||| S:1410 E:1420 ||| NN
which  ||| S:1420 E:1426 ||| WDT
are  ||| S:1426 E:1430 ||| VBP
main  ||| S:1430 E:1435 ||| JJ
molecules  ||| S:1435 E:1445 ||| NNS
of  ||| S:1445 E:1448 ||| IN
Wnt ||| S:1448 E:1451 ||| NNP
/ ||| S:1451 E:1452 ||| NNP
β‑catenin  ||| S:1452 E:1462 ||| NNP
pathway  ||| S:1462 E:1470 ||| NN
were  ||| S:1470 E:1475 ||| VBD
decreased  ||| S:1475 E:1485 ||| VBN
when  ||| S:1485 E:1490 ||| WRB
Bag-1  ||| S:1490 E:1496 ||| NNP
were  ||| S:1496 E:1501 ||| VBD
silenced  ||| S:1501 E:1510 ||| VBN
in  ||| S:1510 E:1513 ||| IN
nanoparticle  ||| S:1513 E:1526 ||| JJ
plasmid  ||| S:1526 E:1534 ||| JJ
complex  ||| S:1534 E:1542 ||| JJ
transfected  ||| S:1542 E:1554 ||| JJ
LoVo  ||| S:1554 E:1559 ||| JJ
cells ||| S:1559 E:1564 ||| NNS
.  ||| S:1564 E:1566 ||| .
These  ||| S:1566 E:1572 ||| DT
results  ||| S:1572 E:1580 ||| NNS
suggest  ||| S:1580 E:1588 ||| VBP
that  ||| S:1588 E:1593 ||| IN
magnetic  ||| S:1593 E:1602 ||| JJ
gold  ||| S:1602 E:1607 ||| NN
nanoparticle  ||| S:1607 E:1620 ||| FW
mediated  ||| S:1620 E:1629 ||| FW
siRNA  ||| S:1629 E:1635 ||| FW
silencing  ||| S:1635 E:1645 ||| FW
Bag-1  ||| S:1645 E:1651 ||| FW
is  ||| S:1651 E:1654 ||| VBZ
an  ||| S:1654 E:1657 ||| DT
effective  ||| S:1657 E:1667 ||| JJ
gene  ||| S:1667 E:1672 ||| NN
therapy  ||| S:1672 E:1680 ||| NN
method  ||| S:1680 E:1687 ||| NN
for  ||| S:1687 E:1691 ||| IN
colon  ||| S:1691 E:1697 ||| NN
cancer ||| S:1697 E:1703 ||| NN
.  ||| S:1703 E:1705 ||| .
